Abbott Laboratories (ABT)

39.20
NYSE : Health Care
Prev Close 38.68
Day Low/High 38.78 / 39.34
52 Wk Low/High 36.00 / 46.22
Avg Volume 8.33M
Exchange NYSE
Shares Outstanding 1.47B
Market Cap 56.95B
EPS 2.90
P/E Ratio 58.61
Div & Yield 1.04 (2.70%)

Latest News

Trump Claims Next Corporate Victims, AT&T-TWX Kick Off Hearing: In Case You Missed It Wednesday

Trump Claims Next Corporate Victims, AT&T-TWX Kick Off Hearing: In Case You Missed It Wednesday

AT&T and Time Warner kicked off a hearing to defend their $84.5 billion merger. AT&T is no stranger to legal battles and anti-trust battles.

Abbott Looks to Kill Alere Deal

Abbott Looks to Kill Alere Deal

The medical device giant files a suit against Alere in the Delaware Court of Chancery hoping to walk away from their $7.9 billion merger agreement.

Abbott Seeks To Terminate Alere Acquisition

Abbott Seeks To Terminate Alere Acquisition

ALERE HAS LOST SIGNIFICANT VALUE DUE TO NUMEROUS DAMAGING BUSINESS DEVELOPMENTS THAT OCCURRED FOLLOWING THE MERGER AGREEMENT

CVS, Abbott Labs Likely to Hike Dividends

Both companies have a track record of raising dividends in December.

Analysts' Actions -- Abbott Labs, Pandora, United Continental, More

Analysts' Actions -- Abbott Labs, Pandora, United Continental, More

Here are Tuesday's top research calls, including upgrades for Pandora and United Continental, and a downgrade for Abbott Labs.

Study: Hospital Nutrition Program Shortens Patient Stays And Reduces Readmissions

Study: Hospital Nutrition Program Shortens Patient Stays And Reduces Readmissions

- FOUR ADVOCATE HEALTH CARE HOSPITALS FOLLOWED MORE THAN 1,200 ADULTS AT-RISK OF MALNUTRITION DURING THEIR STAY[1]

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARII, BPI, CHS, EMXX, GCO, GVP, HAYN, HEES, SMTC, UEPS, XNCR Downgrades: ABT, ACHC, ARL, ARRS, EVK, FSI, NTWK, PIH, WUBA Initiations: PXS Read on to get TheStreet Quant Ratings' detailed report:

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

Abbott Announces CE Mark For I-STAT Alinity, A Pioneering, Handheld Blood Testing Platform

Abbott Announces CE Mark For I-STAT Alinity, A Pioneering, Handheld Blood Testing Platform

- DESIGNED TO BE THE WORLD'S EASIEST-TO-USE WITH-PATIENT TESTING DEVICE

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union regulators are expected to approve Abbott Laboratories' $33 billion acquisition of St. Jude Medical.

Pfizer Finds Breaking Up Is Hard to Do

Pfizer Finds Breaking Up Is Hard to Do

Pfizer stock took a dive. Now what?

Abbott's Absorb™ Bioresorbable Stent Approved As The First Fully Dissolving Heart Stent In Japan

Abbott's Absorb™ Bioresorbable Stent Approved As The First Fully Dissolving Heart Stent In Japan

- Japan approval makes first-of-its-kind medical device available to people in Japan with coronary artery disease who prefer an alternative to a permanent metallic implant

Abbott Files Breach of Contract Suit Against Alere

Abbott Files Breach of Contract Suit Against Alere

Abbott wants more information from Alere, as promised under their pending $7.9 billion agreement.

A Great Place To Work, According To Science

A Great Place To Work, According To Science

TOP SCIENTIST: ABBOTT'S INNOVATION MISSION APPEALS TO 'HEARTS AND MINDS' OF SCIENTISTS

St. Jude Medical Shareholders Approve Merger With Abbott

St. Jude Medical Shareholders Approve Merger With Abbott

St. Jude Medical, Inc.

New Study: Babies Fed Infant Formula With 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies

New Study: Babies Fed Infant Formula With 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies

Levels of FIVE immune markers were nearly identical in breastfed babies and babies fed formula with 2'-FL Human milk oligosaccharide

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.

Abbott Labs Is Likely to See Further Weakness

Abbott Labs Is Likely to See Further Weakness

Look for ABT's declining trend to continue a while longer.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

St. Jude Medical Still a Buy Despite Product Concerns

St. Jude Medical Still a Buy Despite Product Concerns

St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.

Abbott Labs Shares Climb on Better-Than-Expected Earnnigs

Abbott Labs Shares Climb on Better-Than-Expected Earnnigs

Shares of the medical-device giant were climbing after unveiling strong earnings.

Jim Cramer: Drug Stocks Feeling Political Pressure

Jim Cramer: Drug Stocks Feeling Political Pressure

Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.

St. Jude Spars With Muddy Waters After Earnings Miss

St. Jude Spars With Muddy Waters After Earnings Miss

The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.